U.S. markets closed

Aptose Biosciences Inc. (APTO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.7600-1.7700 (-32.01%)
At close: 4:00PM EDT

Aptose Biosciences Inc.

251 Consumers Road
Suite 1105
Toronto, ON M2J 4R3
647 479 9828

Full Time Employees39

Key Executives

NameTitlePayExercisedYear Born
Dr. William G. RiceChairman, Pres & CEO898.83kN/A1959
Dr. Jotin Marango Ph.D., M.D.Sr. VP, CFO, Chief Accounting Officer & Chief Bus. Officer573.66kN/A1979
Dr. Rafael Bejar M.D., Ph.D.Sr. VP & Chief Medical Officer566.92kN/A1972
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed/refractory acute myeloid leukemia. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Corporate Governance

Aptose Biosciences Inc.’s ISS Governance QualityScore as of June 1, 2021 is 9. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.